|Bid||11.52 x 300|
|Ask||12.20 x 1000|
|Day's range||11.53 - 12.06|
|52-week range||3.01 - 14.48|
|PE ratio (TTM)||N/A|
|Earnings date||1 Feb 2017 - 6 Feb 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||14.17|
On a per-share basis, the Morris Plains, New Jersey-based company said it had a loss of 97 cents. Losses, adjusted for non-recurring costs, were 16 cents per share. The results fell short of Wall Street ...
Investors in Immunomedics (IMMU) need to pay close attention to the stock based on moves in the options market lately.
Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: IMMU) under which Seattle Genetics would receive exclusive worldwide rights to develop, manufacture and commercialize sacituzumab govitecan (IMMU-132). Sacituzumab govitecan is an antibody-drug conjugate (ADC) targeted to TROP-2, which is expressed in several solid tumors including cancers of the breast, lung and bladder.